vs
Side-by-side financial comparison of APOGEE ENTERPRISES, INC. (APOG) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $351.4M, roughly 2.0× APOGEE ENTERPRISES, INC.). APOGEE ENTERPRISES, INC. runs the higher net margin — 4.7% vs -104.7%, a 109.5% gap on every dollar of revenue. On growth, APOGEE ENTERPRISES, INC. posted the faster year-over-year revenue change (1.6% vs -3.7%). Over the past eight quarters, APOGEE ENTERPRISES, INC.'s revenue compounded faster (2.9% CAGR vs -2.9%).
Apogee Electronics is an American manufacturer of audio interfaces, analog-to-digital and digital-to-analog converters, USB & iOS microphones, and audio production software.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
APOG vs QDEL — Head-to-Head
Income Statement — Q4 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $351.4M | $699.9M |
| Net Profit | $16.6M | $-733.0M |
| Gross Margin | 22.4% | — |
| Operating Margin | 7.3% | -100.7% |
| Net Margin | 4.7% | -104.7% |
| Revenue YoY | 1.6% | -3.7% |
| Net Profit YoY | 568.8% | -3583.4% |
| EPS (diluted) | $0.78 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $351.4M | — | ||
| Q4 25 | $348.6M | — | ||
| Q3 25 | $358.2M | $699.9M | ||
| Q2 25 | $346.6M | $613.9M | ||
| Q1 25 | $345.7M | $692.8M | ||
| Q4 24 | $341.3M | $707.8M | ||
| Q3 24 | $342.4M | $727.1M | ||
| Q2 24 | $331.5M | $637.0M |
| Q1 26 | $16.6M | — | ||
| Q4 25 | $16.5M | — | ||
| Q3 25 | $23.6M | $-733.0M | ||
| Q2 25 | $-2.7M | $-255.4M | ||
| Q1 25 | $2.5M | $-12.7M | ||
| Q4 24 | $21.0M | $-178.4M | ||
| Q3 24 | $30.6M | $-19.9M | ||
| Q2 24 | $31.0M | $-147.7M |
| Q1 26 | 22.4% | — | ||
| Q4 25 | 23.8% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 21.7% | — | ||
| Q1 25 | 21.6% | — | ||
| Q4 24 | 26.1% | — | ||
| Q3 24 | 28.4% | — | ||
| Q2 24 | 29.8% | — |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 7.1% | — | ||
| Q3 25 | 7.5% | -100.7% | ||
| Q2 25 | 2.0% | -29.4% | ||
| Q1 25 | 1.8% | 4.7% | ||
| Q4 24 | 8.4% | -14.2% | ||
| Q3 24 | 12.3% | 2.1% | ||
| Q2 24 | 12.5% | -18.4% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 6.6% | -104.7% | ||
| Q2 25 | -0.8% | -41.6% | ||
| Q1 25 | 0.7% | -1.8% | ||
| Q4 24 | 6.1% | -25.2% | ||
| Q3 24 | 8.9% | -2.7% | ||
| Q2 24 | 9.4% | -23.2% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.77 | — | ||
| Q3 25 | $1.10 | $-10.78 | ||
| Q2 25 | $-0.13 | $-3.77 | ||
| Q1 25 | $0.12 | $-0.19 | ||
| Q4 24 | $0.96 | $-2.54 | ||
| Q3 24 | $1.40 | $-0.30 | ||
| Q2 24 | $1.41 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $39.5M | $98.1M |
| Total DebtLower is stronger | $232.3M | $2.5B |
| Stockholders' EquityBook value | $511.8M | $2.0B |
| Total Assets | $1.1B | $5.7B |
| Debt / EquityLower = less leverage | 0.45× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $39.5M | — | ||
| Q4 25 | $41.3M | — | ||
| Q3 25 | $39.5M | $98.1M | ||
| Q2 25 | $32.8M | $151.7M | ||
| Q1 25 | $41.4M | $127.1M | ||
| Q4 24 | $43.9M | $98.3M | ||
| Q3 24 | $51.0M | $143.7M | ||
| Q2 24 | $30.4M | $107.0M |
| Q1 26 | $232.3M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | $285.0M | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | $511.8M | — | ||
| Q4 25 | $512.3M | — | ||
| Q3 25 | $500.2M | $2.0B | ||
| Q2 25 | $481.8M | $2.8B | ||
| Q1 25 | $487.9M | $3.0B | ||
| Q4 24 | $522.1M | $3.0B | ||
| Q3 24 | $506.4M | $3.2B | ||
| Q2 24 | $480.0M | $3.2B |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | $5.7B | ||
| Q2 25 | $1.2B | $6.4B | ||
| Q1 25 | $1.2B | $6.5B | ||
| Q4 24 | $1.2B | $6.4B | ||
| Q3 24 | $917.1M | $6.8B | ||
| Q2 24 | $889.0M | $6.7B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | 0.58× | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $122.5M | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | 7.8% | 7.0% |
| Cash ConversionOCF / Net Profit | 7.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $122.5M | — | ||
| Q4 25 | $29.3M | — | ||
| Q3 25 | $57.1M | $-45.5M | ||
| Q2 25 | $-19.8M | $-46.8M | ||
| Q1 25 | $30.0M | $65.6M | ||
| Q4 24 | $31.0M | $63.7M | ||
| Q3 24 | $58.7M | $117.9M | ||
| Q2 24 | $5.5M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $22.9M | — | ||
| Q3 25 | $52.4M | $-94.7M | ||
| Q2 25 | $-26.9M | $-84.3M | ||
| Q1 25 | $19.1M | $9.4M | ||
| Q4 24 | $22.0M | $16.5M | ||
| Q3 24 | $50.2M | $71.4M | ||
| Q2 24 | $-1.8M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 14.6% | -13.5% | ||
| Q2 25 | -7.8% | -13.7% | ||
| Q1 25 | 5.5% | 1.4% | ||
| Q4 24 | 6.4% | 2.3% | ||
| Q3 24 | 14.7% | 9.8% | ||
| Q2 24 | -0.5% | -20.9% |
| Q1 26 | 7.8% | — | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.3% | 7.0% | ||
| Q2 25 | 2.1% | 6.1% | ||
| Q1 25 | 3.2% | 8.1% | ||
| Q4 24 | 2.6% | 6.7% | ||
| Q3 24 | 2.5% | 6.4% | ||
| Q2 24 | 2.2% | 5.5% |
| Q1 26 | 7.37× | — | ||
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 12.08× | — | ||
| Q4 24 | 1.48× | — | ||
| Q3 24 | 1.92× | — | ||
| Q2 24 | 0.18× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
